Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) Profit After Tax (2020 - 2025)

Relay Therapeutics (RLAY) has disclosed Profit After Tax for 6 consecutive years, with -$54.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax rose 27.78% to -$54.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$276.5 million, a 18.13% increase, with the full-year FY2025 number at -$276.5 million, up 18.13% from a year prior.
  • Profit After Tax was -$54.9 million for Q4 2025 at Relay Therapeutics, up from -$74.1 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$42.2 million in Q1 2021 to a low of -$193.4 million in Q2 2021.
  • A 5-year average of -$80.5 million and a median of -$76.4 million in 2022 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 623.69% in 2021, then surged 60.3% in 2022.
  • Relay Therapeutics' Profit After Tax stood at -$67.5 million in 2021, then dropped by 0.07% to -$67.5 million in 2022, then fell by 23.69% to -$83.5 million in 2023, then grew by 8.97% to -$76.0 million in 2024, then grew by 27.78% to -$54.9 million in 2025.
  • Per Business Quant, the three most recent readings for RLAY's Profit After Tax are -$54.9 million (Q4 2025), -$74.1 million (Q3 2025), and -$70.4 million (Q2 2025).